367259-04-9

Upstream product

• 4724-10-1 methyl 2-(3,5-dihydroxyphenyl)acetate 
• 74-88-4 methyl iodide 
• 50637-26-8 methyl 3-(benzyloxy)-5-methoxybenzoate 
• 50637-28-0 (3-(benzyloxy)-5-methoxyphenyl)methanol 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 628330-11-0 (3-benzyloxy-5-methoxyphenyl)acetonitrile 
• 628330-12-1 methyl (3-benzyloxy-5-methoxyphenyl)acetate 
• 4670-09-1 2-(3,5-dihydroxyphenyl)acetic acid 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 

Downstream Products

• 1056453-99-6 [3-(3-bromo-phenoxy)-5-methoxy-phenyl]-acetic acid methyl ester 
• 1056453-39-4 (3-methoxy-5-trifluoromethanesulfonyloxy-phenyl)-acetic acid methyl ester 
• 1056986-94-7 C₁₇H₁₄ClNO₄ 

Relevant academic research and scientific papers

First total synthesis of medicinally important 3,4,7-trimethoxy-9,10-dihydrophenanthrene-1,5-diol

The first total synthesis was successfully achieved for biologically active 9,10-dihydrophenanthrene-1,5-diol. The key features of our synthetic approach are Perkin condensation, followed by bromination, palladium mediated intramolecular C-C bond coupling, and selective isopropyl ether cleavage. Synthesized compounds were purified and characterized by IR, 1HNMR, 13CNMR and HRMS/LC-MS.

PPAR ACTIVE COMPOUNDS

Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.

ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON

A compound of the formula (I): pharmaceutically acceptable salt or solvate thereof, wherein Y is a group of the formula: wherein Ring A is optionally substituted aryl or optionally substituted heteroaryl, X3 is COOR17 or the like Y i

NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARγ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R1-R5, R7a, R7b, R7c, R8-R10, X1, X2 m, n, o and p are as defined herein.

1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY

A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, - O -, - S - and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.